施贵宝公布的数据显示,其药物Mezikd在临床试验中取得了更高的总体缓解率,并且观察到达到完全缓解或更佳疗效的患者比例有所提升。
施贵宝公布的数据显示,其药物Mezikd在临床试验中取得了更高的总体缓解率,并且观察到达到完全缓解或更佳疗效的患者比例有所提升。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.